Study of BCMA CAR-T in Multiple Myeloma

Inclusion Criteria: * 1\. 18 years to 70 years, expected survival \> 3 months; * 2\. Confirmed diagnosis of active MM as defined by IMWG. BCMA expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry. * 3\. BCMA-expressing B cell malignancy must be assured and must be relapsed or refractory disease.； * 4\. ECOG performance status of 0-2; * 5\. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney: Cr≤1.25ULN; * 6\. No serious allergic constitution; * 7\. No other serous diseases that conflicts with the clinical program; * 8\. No other cancer history; * 9\. female participants of reproductive potential must have a negative serum pregnancy test; * 10\. Subjects must have signed written, informed consent. Exclusion Criteria: * 1\. Pregnant or lactating women; * 2\. Uncontrolled active infection, HIV infection, syphilis serology reaction positive; * 3\. Active hepatitis B or hepatitis C infection; * 4\. Recent or current use of glucocorticoid or other immunosuppressor; * 5\. serious mental disorder; * 6\. With severe cardiac, liver, renal insufficiency, diabetes and other diseases; * 7\. Participate in other clinical research in the past three months; previously treatment with any gene therapy products;